P47 suppresses metastasis of HER2-positive breast cancer
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
List view / Grid view
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
We had the privilege of speaking to Dr Víctor Sebastián Pérez, Associate Director of Computational Drug Design, following his presentation at ELRIG UK 2023. He shares his insights into how Exscientia is using AI to design drug candidates for cancer treatment.
Researchers have uncovered the role of the PL-BLA neuronal axis and its potential function in DOP-mediated anxiolytic effects.
Researchers have created dual-targeted CARs, which performed better than single-targeted CARs in both in vivo and in vitro experiments.
The new study suggests that this gene therapy method may combat ARVC in both early and more advanced stages of the condition.
How pure consistent and functional lower motor neurons can be precision reprogrammed from iPSCs for motor neuron disease research and drug discovery.
In vitro and in vivo experiments highlight the advantages of a new targeted spectroscopy system for many eye diseases.
Researchers found heightened SCAN enzyme activity in humans and mice with diabetes results in excessive nitric oxide on insulin receptors.
Advancements in enzyme-activated near-infrared fluorescent probes hold promise for evaluating responses to enzyme-targeting therapies.
Mitochondrial fragmentation mechanism that can cause ventilator-induced diaphragm dysfunction (VIDD) found, and a therapeutic to mitigate it.
Research suggests immune and non-immune cells can be reprogrammed by changing how nutrients are used.
A collaborative team has uncovered a method to extend the functionality of CAR-T cells.
Researchers from Brazil discovered that survival of the parasitic worm that cause the disease schistosomiasis, depends on expression of a specific type of RNA. In animal trials, inhibition of the molecule interrupted the infection.
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
Japanese researchers successfully engineered iPSCs to secrete a modified enzyme, mNAGA, and restored enzyme activity in vitro and in a mouse model, opening new avenues for regenerative medicine for conditions such as Fabry Disease.